NetworkNewsBreaks – Willow Biosciences Inc. (TSX
Post# of 23
Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a Vancouver, Canada-based company focused on manufacturing pharmaceutical-grade cannabinoids via synthetic biology, has closed its previously announced upsized public offering of 17,692,307 units of the company, each at a price of $0.65, including 2,307,692 units issued pursuant to the full exercise of the over-allotment option. The company secured aggregate gross proceeds of approximately $11.5 million in the offering. Williow Biosciences expects to use net proceeds for the commercialization of cannabigerol (“CBG”) and other portfolio cannabinoids of the company, general and administrative expenses, working capital and general corporate purposes.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer